Next-Generation Sequencing In-Depth Focus 2016
Posted: 11 December 2016 | Michael W. Pfaffl, Pushpanathan Muthuirulan | 2 comments
NGS technologies have been employed in a wide range of areas in drug discovery, including drug target identification, biomarker discovery and biopharmaceutics development. Pushpanathan Muthuirulan of the National Institutes of Health gives us an overview of this in his article in our NGS In-Depth Focus. Meanwhile, the possibilities that RNA-Seq offers in molecular diagnostics and clinical research, as an alternative method to RT-qPCR, are covered in an article by Michael W. Pfaffl at TUM School of Life Sciences.
This Next-Generation Sequencing In-Depth Focus is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
- quarterly issues in print and/or digital format
- case studies, whitepapers, webinars and industry-leading content
- breaking news and features
- our extensive online archive of thousands of articles and years of past issues
- ...And it's all free!
Click here to Subscribe today Login here
Related organisations
National Institutes of Health (NIH), Technical University of Munich (TUM)
Related people
Michael W. Pfaffl, Pushpanathan Muthuirulan
please send to me the paper
Hi Vassilis, you can read the paper by becoming a member.